Higenamine as a Potential Pharmacologic Stress Agent in the Detection of Coronary Artery Disease |
| |
| Authors: | Nana Zhang Zijian Li Haibo Zhu |
| |
| Institution: | 1. Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences, Beijing 100050, China;2. Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences Ministry of Education, and Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100050, China;3. State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China;1. Department of Health Statistics, School of Public Health, Tianjin Medical University, Tianjin 300070, China;2. Department of Medical Imaging, Peking University First Hospital, Beijing 100034, China;1. Administration Office of Science and Technology Projects, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;2. Institute of Medical Information, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100020, China;3. Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;1. Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;2. Department of Adult Cardiac Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;3. Department of Surgical Intensive Care Unit, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;4. Department of Cardiopulmonary Bypass, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;5. Department of Transfusion, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;6. Department of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;7. Department of Pharmacy, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China;1. Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China;2. Cadre Medical Department, Beijing Aerospace General Hospital, Beijing 100076, China;3. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, the Ministry of Education Key Laboratory, Beijing 100730, China;1. Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;2. National Institute of Health Data Science, Peking University, Beijing 100191, China;3. School of Public Health, Peking University, Beijing 100191, China;4. Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China |
| |
| Abstract: | Myocardial perfusion imaging (MPI) is valuable for the diagnosis, prognosis, and management of coronary artery disease (CAD). The most commonly used pharmacologic stress agents at present are vasodilators and adrenergic agents. However, these agents have contraindications and may cause adverse effects in some patients. Thus, other stress agents feasible for more patients are required. Higenamine (HG) is a β-adrenergic receptor agonist currently approved for clinical trials as a stress agent for myocardial infarction. It also has a promising value in MPI for the detection of CAD in preclinical and clinical studies. This review summarizes the application of HG on MPI, including its mechanism of action, stress protocol, efficacy, and safety. |
| |
| Keywords: | coronary artery disease higenamine myocardial perfusion imaging stress agent |
| 本文献已被 ScienceDirect 等数据库收录！ |
| 点击此处可从《中国医学科学杂志》浏览原始摘要信息 |
| 点击此处可从《中国医学科学杂志》下载免费的PDF全文 |
|
